Belfast Health and Social Care Trust
caring supporting improving together

FOI/38494

29 October 2026

High Cost Drugs Ophthalmology May - August 2026

1. **For the 4 months from May to August 2026:, how many unique* patients received the following intra-vitreal treatments for any eye condition:**

   Aflibercept (Eylea)

   1,692

   Aflibercept (Eylea 8mg - Eylea HD)

   As above

   Aflibercept (Biosimilar, examples include but are not limited to Eydenzelt, Mynzepli or Vgenfli)

   As above

   Bevacizumab

   4

   Brolucizumab

   0

   Dexamethasone

   15

   Faricimab

   2,946

   Ranibizumab

   139

   Fluocinolone acetonide

   10

   ***Please count a patient only once for any treatment, regardless of how many injections or implants they may have received**

29 October 2026

2. For the patients above, how many were new to intra-vitreal treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Aflibercept (Eylea)

12

Aflibercept (Eylea 8mg - Eylea HD)

As above

Aflibercept (Biosimilar, examples include but are not limited to Eydenzelt, Mynzepli or Vgenfli)

As above

Bevacizumab

3

Brolucizumab

0

Dexamethasone

4

Faricimab

51

Ranibizumab

3

Fluocinolone acetonide

2